Physician profile
James E Sligh
NPI 1366539462
$237,899.89
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75K · 2020: $28K · 2021: $67K · 2022: $67K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $223,196.59 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $9,768.57 | 2019-2020 | |
| Genzyme Corporation | $4,345.29 | 2019-2021 | |
| Biofrontera INC. | $121.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $108.50 | 2019-2020 | |
| Janssen Biotech, INC. | $85.28 | 2019 | |
| Sun Pharmaceutical Industries INC. | $70.31 | 2019 | |
| Abbvie INC. | $68.33 | 2019-2020 | |
| Musculoskeletal Transplant Foundation INC. | $44.93 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.00 | 2019 | |
| Prugen, INC. Pharmaceuticals | $19.42 | 2019 | |
| Leo Pharma INC. | $15.81 | 2019 | |
| Lilly USA, LLC | $12.59 | 2019 | |
| Organogenesis INC. | $12.42 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sligh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.